Phoenix Biotech Acquisition Corp. (PBAX) Stock

About Phoenix Biotech Acquisition Corp.

Phoenix Biotech Acquisition Corp. currently lacks substantial business operations. The company's primary objective is to complete a strategic business combination, such as a merger, asset acquisition, share exchange, or other form of reorganization, with one or more suitable enterprises. Its focus is on identifying and integrating with a firm engaged in the healthcare or healthcare-related industries within the United States or Europe. This entity was established in 2021 and maintains its headquarters in Oakland, California.

Phoenix Biotech Acquisition Corp. is headquartered in US.

Phoenix Biotech Acquisition Corp. (PBAX) stock trades at $5.85 with a market capitalization of $36.47M. The stock is valued at a negative price-to-earnings (P/E) ratio of -0.26, reflecting a net loss over the last twelve months, a negative price-to-book of -18.17, reflecting negative shareholders' equity, price-to-sales of 0.00. Over the past 52 weeks the stock has ranged between $4.12 and $12.80, and currently trades 54.3% below its 52-week high.

On profitability, Phoenix Biotech Acquisition Corp. generates a return on equity (ROE) of 1920.00% (not meaningful, as shareholders' equity is negative), return on capital employed of 201.25%.